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Serum concentrations of lathosterol, the plant sterols campesterol and sitosterol and the cholesterol metabolite
5α-cholestanol are widely used as surrogate markers of cholesterol synthesis and absorption, respectively.
Increasing numbers of laboratories utilize a broad spectrum of well-established and recently developed methods
for the determination of cholesterol and non-cholesterol sterols (NCS). In order to evaluate the quality of these
measurements and to identify possible sources of analytical errors our group initiated the first international
survey for cholesterol and NCS. The cholesterol and NCS survey was structured as a two-part survey which took
place in the years 2013 and 2014. The first survey part was designed as descriptive, providing information about
the variation of reported results from different laboratories. A set of two lyophilized pooled sera (A and B) was
sent to twenty laboratories specialized in chromatographic lipid analysis. The different sterols were quantified
either by gas chromatography-flame ionization detection, gas chromatography- or liquid chromatography-mass
selective detection. The participants were requested to determine cholesterol and NCS concentrations in the
provided samples as part of their normal laboratory routine. The second part was designed as interventional
survey. Twenty-two laboratories agreed to participate and received again two different lyophilized pooled sera
(C and D). In contrast to the first international survey, each participant received standard stock solutions with
defined concentrations of cholesterol and NCS. The participants were requested to use diluted calibration solutions from the provided standard stock solutions for quantification of cholesterol and NCS. In both surveys,
each laboratory used its own internal standard (5α-cholestane, epicoprostanol or deuterium labelled sterols).
Main outcome of the survey was, that unacceptably high interlaboratory variations for cholesterol and NCS
concentrations are reported, even when the individual laboratories used the same calibration material. We
discuss different sources of errors and recommend all laboratories analysing cholesterol and NCS to participate in
regular quality control programs.

1. Introduction

concentrations routinely determined by different laboratories in
Europe, North and South America. Here, we reflect the comparability of
cholesterol and NCS concentrations determined by different separation
and detection methods and discuss the suitability of different compounds used as internal standards for sterol quantification. Twenty laboratories specialized in chromatographic lipid analysis, by either gasor liquid-chromatography were enrolled to participate in this first
survey part. The second part of the international cholesterol and neutral
sterol survey took place one year later in 2014. Twenty-two laboratories
participated in the second survey whereof five laboratories attended for
the first time. Contrary to the first survey, the second was designed as
an interventional trial. The focus was on the influence of the utilized
calibration solutions and the participants were requested to use provided stock solutions for the quantification of the sample material.

Serum or plasma concentrations of the cholesterol precursors lanosterol, lathosterol, and desmosterol are widely used as surrogate
markers of endogenous cholesterol synthesis [1]. The cholesterol metabolite 5α-cholestanol and the plant sterols campesterol and sitosterol
are used as markers of cholesterol absorption [2,3]. These non-cholesterol sterols (NCS) show even stronger correlations with cholesterol
absorption and synthesis when expressed as ratios to total cholesterol,
which standardizes for variations in sterol transport protein concentrations [4]. Specifically, when reporting NCS as their ratios to
cholesterol, the cholesterol measurement should ideally be performed
from the same sample preparation as for the NCS analysis. The interest
in surrogate markers of cholesterol metabolism is recently increasing
and more laboratories develop new methods for the determination of
cholesterol and NCS using different chromatographic separation and
mass spectrometric detection methods. Conflicting absolute and cholesterol-corrected NCS concentrations are reported in the literature
making it difficult or nearly impossible to define cut-off values [5–7] or
to compare absolute or cholesterol corrected values from different
studies in meta-analysis. For a better comparison of reported values and
the identification of methodological sources of errors, we planned and
performed the first international surveys for cholesterol and NCS. The
first part of the cholesterol and NCS survey was initiated in the year
2013 under the expertise of the German Reference Institute for Bioanalytics (RfB) and the Laboratory for Specialized Lipid Diagnostic of the
University Hospital, both located in Bonn, Germany. The aim of the first
survey was to investigate the variations in cholesterol and NCS

2. Materials and methods
The participants submitted results from six different methods for
sterol determination: capillary gas chromatography-flame ionisation
detection (GC-FID) with either 5α-cholestane (5α-chol) or epicoprostanol (epi) as internal standard (GC-FID-5α-chol and GC-FID-epi, respectively), capillary GC-mass selective detection (MSD) with either 5αchol, epi or deuterium labelled sterols as internal standards (GC-MSD5α-chol, GC-MSD-epi and GC-MSD-deuterium, respectively) and high
performance-liquid chromatography (HPLC) with MSD and deuterated
sterols (LC-MSD-deuterium) used as internal standard. Since each laboratory was requested to use its specific routine analytical method, the
work-up procedure and determination setting are strikingly different
for the individual participants. Table 1 shows an overview of the reported sample work-up conditions, chemicals, chromatographic columns, and instrumentation for GC analyses used in the surveys. Most of
the laboratories used alkaline hydrolysis in order to deconjugate fatty
acid esterified sterols and thus analysing total serum sterol concentrations after derivatisation of the free hydroxyl groups. One laboratory,

1

These authors contributed in setting up the protocol (IB, DL, UD, H-FS),
preparing standard solutions (UD, AL-S, AK, SF), preparing and distributing the
lyophilized standard samples A-D (W-JG, H-FS, DL), evaluating the data (W-JG,
H-FS, DL), calculating statistics (W-JG, H-FS, DL), and finally in preparing the
first draft of the manuscript (IB, DL, UD, H-FS).
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Table 1
Methodological parameters and instrumental equipment from the different contributors.
sample volume [μL]
hydrolysis time [min]
hydrolysis temperature [°C]
hydrolysis NaOH/KOH concentration [mol/L]
extraction solvents
solvent volume for extraction [mL]
silylation time [min]
silylation temperature [°C]
silylation reagents (GC only)
Injection volume [μL]
split mode injection (GC only)
column lenght (GC only) [m]
column diameter (GC only) [mm]
column film thickness (GC only) [μm]
columns (GC only)
separation instruments (GC only)
detectors

10; 20; 40; 50; 100; 200; 250; 300; 400; 500; 1000
15; 20; 60; 65; 68; 70; 90; 120
50; 60; 80; 90
0.35; 0.5; 0.71; 1.0; 1.78; 2.0
hexane; petroleum ether; petroleum ethyl ether; chloroforme; tetrachlorethylene; cyclohexane; isooctane; heptane
2; 3; 4; 5; 9; 20
30; 45; 60; over night
37; 55; 60; 70
HMDS/TMCS/pyridine (3:1:9)(Supelco) dimethylformamide/HMDS/TMCS Sylon BFT BSTFA/TMCS 99:1 + pyridine TriSil reag
(Thermo Fischer) HMDS/TMCS/Pyridine 2:1:3 MSTFA
1; 2; 3; 25; 40
1:3; 10:1; 12:1; 15:1; 20:1; splitless
25; 30
0.22; 0.25; 0.32
0.1; 0.25
SUPELCO SAC™-5 Capillary GC Column HP-Ultra2 SAC-5 capilary column DB-5-MS Restek RXI 1 mS (100% dimethyl
polysiloxane) CP_SIL_5CB HAT-5 carbone modified siloxane HP-5MS 5% phenylmethyl siloxane
GC-Agilent Technologies 6890 N GC-Agilent 7890A GC-Shimazu GC-17A FID GC-HP4890 Shimadzu GC-MSQP2010
Flame ionisation detector Mass selective detector 5975c inert xl ms Ion Trap AgilentMS 5973 N 4000 Qtrap triple quad SCIEX
API 3000 triple quadrupol Photospray Thermo TSQ8000 Triple quad

The data were submitted in the units individually used by the participant (ng/mL, mg/mL, μg/dL, mg/dL, mg/L, μmol/L, mmol/L) and
converted into standard units for comparison (cholesterol and NCS as
mg/dL). Each participant received the results presented in form of
Youden-Plots and basic statistical data. The evaluated data were given
in the individual units, which were used by the participant.

using LC-MSD, quantified free and esterified fraction of the freeze-dried
test-samples in order to calculate the total concentration. Some laboratories used fully automated peak integration and quantitation
software belonging to the software package of the supplier. Others integrated the individual peaks half-automatically using self-created integration and evaluation macros with the option to supervise and correct integration of each peak. It should be emphasized that the
individual sample work-up procedures or detection specifications
cannot be reported within this article because of the anonymization of
the participants. Since the freeze-dried serum samples were routinely
used in round-robin tests of the RfB, it was possible to give a reference
value (target concentration) only for cholesterol. The lyophilized serum
samples were additionally used to measure other parameters in clinical
routine biochemistry such as triglycerides, total protein or subspecies
proteins such as albumin or gamma globuline in additional ring trials in
Germany. All these parameters were within the normal range as characterized by reference values except for triglycerides in sample D of the
second ring trial, where the median level was marginally increased
(data not shown). Single values more than 50% different from the mean
value of all submitted sterol concentrations have a marked effect on the
mean values of the whole participant group. Therefore, individual values more than 50% different from the mean value were regarded as
outliers and several of the above-mentioned parameters were additionally calculated without the outlier values and reported within the
script. The guidelines of the German Medical Association for quality
assurance of clinical laboratory investigations tolerates relative deviations for cholesterol within external proficiency testing of up to 13%
[8]. Due to the relatively small number of participants in our surveys
we set a relative deviation, that can be considered as acceptable
to ± 15% of the mean value of the included participants. The mean
values, standard deviation, minimum and maximum values of all participants as well as the ratios of 5α-cholestanol, lathosterol, campesterol
to cholesterol and the ratio lathosterol to campesterol are listed in
Tables 2 and 3 and shown in Figs. 1 and 2.

2.2. The second international cholesterol and NCS survey
Twenty-two laboratories participated in the second survey whereof
the results of five laboratories were included that attended for the first
time. Two groups that attended the first survey were not able to participate in the second survey. Again a set of two different lyophilized
pooled sera (sample C and D) was sent to each participant and analysed
with the individual determination method used in the routine operation
of each laboratory. Contrary to the first survey the second part was
designed as an interventional trial with focus on the influence of the
utilized calibration solutions on cholesterol and NCS concentrations.
Therefore, the participants were requested to use the in glass ampoules
provided stock solutions (containing cholesterol, 5α-cholestanol, lathosterol, campesterol, and sitosterol in the concentrations 1.0 mg/mL;
18.8 μg/mL, 18.8 μg/mL, 13.0 μg/mL, and 18.0 μg/mL; respectively).
The stock solutions for the quantification of the sample material were
generously provided by the Department of Laboratory Medicine,
Division of Clinical Chemistry, Karolinska University Hospital,
Karolinska Institutet, Huddinge, Sweden. All non-cholesterol sterols for
the quantification of the sample material were purchased from SigmaAldrich. Data collection and result transmission procedure was identically to the above described protocol of the first survey part.
2.3. Statistical analysis
Statistical parameters (mean values, standard deviations, coefficients of variation, maximum and minimum values) of the submitted
concentrations of all participating laboratories were calculated.
Conditions that impede a clear and strong statistical evaluation of the
data set are the fact that different laboratories participated in the two
surveys (only twelve laboratories participated in both surveys). For that
reason, only a qualitative discussion of the data set is performed.

2.1. The first international cholesterol and NCS survey
Twenty laboratories specialized in chromatographic lipid analysis
participated in this survey. A set of two different lyophilized pooled
sera (sample A and B) was sent to each participant and analysed with
the individual determination method during the routine operation of
each laboratory. After a period of twelve weeks the participants were
requested to submit their results to RfB for further data analysis.
Eighteen of the twenty participating laboratories submitted their results
before the 12-week deadline and were included for further evaluation.

3. Results and discussion
The results and subgroup analysis of cholesterol and NCS from the
both surveys are listed in Table 2 and shown in Fig. 1, A1 to E2.
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1)

118

0.51 ± 0.44
0.21 ± 0.18
1.33
0.48 ± 0.12
0.35
0.84 ± 0.58

0.22 ± 0.20
0.15 ± 0.06
0.14
0.39 ± 0.44
0.14 ± 0.05
0.26 ± 0.23

0.60 ± 0.32
0.49 ± 0.07
0.66 ± 0.61
0.49 ± 0.22
0.51 ± 0.29
0.86 ± 0.29

0.33 ± 0.33
0.21 ± 0.04
0.07
0.62 ± 0.78
0.28 ± 0.08
0.24 ± 0.09
0.46 ± 0.22

total cholestanol
GC-FID (5α-cholestane)
GC-MS (5α-cholestane)
GC-MS (epicoprostanol)
GC-MS (deuterium)
LC-MS (deuterium)

total lathosterol
GC-FID (5α-cholestane)
GC-FID (epicoprostanol)
GC-MS (5α-cholestane)
GC-MS (epicoprostanol)
GC-MS (deuterium)

total campesterol
GC-FID (5α-cholestane)
GC-MS (5α-cholestane)
GC-MS (epicoprostanol)
GC-MS (deuterium)
LC-MS (deuterium)

total sitosterol
GC-FID (5α-cholestane)
GC-FID (epicoprostanol)
GC-MS (5α-cholestane)
GC-MS (epicoprostanol)
GC-MS (deuterium)
LC-MS (deuterium)
1.51
0.34
0.32
0.70

1.51
0.25

1.36
0.54
1.36
0.65
0.91
1.13

0.70
0.18
0.59

0.70
0.22

1.25

0.56

1.33
0.38

236

199

190

0.40 ± 0.35
0.27 ± 0.04
0.13
0.68 ± 0.80
0.36 ± 0.11
0.30 ± 0.13
0.56 ± 0.26

0.76 ± 0.41
0.66 ± 0.13
0.85 ± 0.67
0.64 ± 0.27
0.61 ± 0.50
1.08 ± 0.35

0.26 ± 0.21
0.19 ± 0.08
0.18
0.42 ± 0.46
0.17 ± 0.06
0.30 ± 0.24

0.63 ± 0.53
0.26 ± 0.25
1.57
0.63 ± 0.18
0.41
1.01 ± 0.75

235
238 ± 65
219

224 ± 16
118
203 ± 35

coefficient of variation,

0.09
0.23
0.11
0.28

126.6%
28.6%
38.9%
47.5%
2)

0.07
0.16

0.27
0.39
0.27
0.34
0.29
0.55

100.2%
17.1%

53.8%
14.2%
92.5%
44.7%
57.5%
34.0%

0.07
0.10
0.13

114.6%
39.4%
88.0%

0.43

69.5%
0.07
0.08

0.39

25.4%

91.0%
42.9%

0.02
0.02

85.1%
86.6%

166

123

23.6%

24.6%

161

8.8%

mean value with standard deviation [mg/dL],

196
201 ± 49
169

173 ± 15
84
161 ± 38

max4)
236

3)

0.12
0.28
0.12
0.35

0.12
0.21

0.10
0.47
0.38
0.45
0.10
0.71

0.10
0.13
0.16

0.10
0.10

0.48

0.50

0.02
0.02

192

176

208

min3)
118

1.60
0.44
0.42
0.85

1.60
0.30

1.62
0.78
1.62
0.83
1.25
1.41

0.75
0.22
0.66

0.75
0.30

1.54

0.75

1.57
0.48

285

242

241

max4)
285

4)

40.2%
1.5%
24.6%
43.3%

46.8%
35.6%

56.5%
17.0%
48.2%
54.1%
36.5%
30.0%

52.7%
41.6%
28.4%

43.5%
54.0%

68.3%
26.3%
82.2%
19.2%
82.3%

33.8%
16.3%
20.2%
27.3%

14.2%

CV2)
28.9%

0.19
0.18
0.14
0.32

0.14
0.15

0.19
0.21
0.19
0.36
0.26
0.72

0.06
0.20
0.12

0.06
0.15

0.03
0.20
0.21
0.38
0.03

102
108
129
103

118

min3)
102

maximum value [mg/dL],

0.29 ± 0.12
0.18 ± 0.00
0.19 ± 0.05
0.46 ± 0.20

0.25 ± 0.12
0.24 ± 0.09

0.44 ± 0.25
0.25 ± 0.04
0.41 ± 0.20
0.58 ± 0.31
0.38 ± 0.14
0.91 ± 0.27

0.16 ± 0.08
0.28 ± 0.12
0.18 ± 0.05

0.20 ± 0.09
0.22 ± 0.12

0.38 ± 0.26
0.24 ± 0.06
0.51 ± 0.42
0.44 ± 0.08
0.23 ± 0.19
0.88

140 ± 20
277
134 ± 45
122 ± 20
151 ± 30
143 ± 39
139

mean ± SD1)
147 ± 43

minimum value [mg/dL],

118.0%
30.9%
43.0%
46.6%

88.0%
15.2%

54.0%
20.1%
78.9%
41.6%
82.0%
32.4%

108.7%
37.8%
81.4%

80.5%
43.3%

73.9%

28.1%

83.9%
93.2%

27.5%

17.0%

7.3%

CV2)
21.6%

mean ± SD1)
211 ± 45

min3)
84

mean ± SD1)
168 ± 42

CV2)
25.1%

Sample C

Sample B

Sample A

GC-FID (5α-cholestane)
GC-FID (epicoprostanol)
GC-MS (5α-cholestane)
GC-MS (epicoprostanol)
GC-MS (deuterium)
LC-MS (deuterium)
Target5)

total cholesterol

Second survey

First survey

Table 2
Results of absolute cholesterol and non-cholesterol sterols submitted by GC–MS and LC–MS methods.

5)

0.35 ± 0.25
0.30 ± 0.01
0.30 ± 0.07
0.78 ± 0.45

0.39 ± 0.24
0.40 ± 0.24

0.68 ± 0.46
0.38 ± 0.07
0.55 ± 0.28
0.94 ± 0.57
0.58 ± 0.19
1.56 ± 0.81

0.19 ± 0.15
0.44 ± 0.19
0.26 ± 0.08

0.28 ± 0.15
0.34 ± 0.17

0.56 ± 0.45
0.38 ± 0.10
0.60 ± 0.48
0.60 ± 0.32
0.32 ± 0.26
1.66

209 ± 35
421
214 ± 69
171 ± 44
239 ± 54
201 ± 89
216

mean ± SD1)
220 ± 73

71.1%
4.8%
23.8%
58.1%

61.3%
58.4%

67.7%
17.9%
50.2%
60.9%
33.4%
51.9%

80.1%
44.0%
30.8%

51.8%
50.5%

79.6%
26.7%
80.4%
53.6%
81.3%

32.2%
25.8%
22.4%
44.1%

16.8%

CV2)
33.0%

0.08
0.29
0.20
0.46

0.08
0.21

0.27
0.32
0.27
0.53
0.39
0.99

0.03
0.30
0.17

0.03
0.24

0.04
0.31
0.26
0.37
0.04

165
140
201
113

178

min3)
113

determined by reference institute.

0.45
0.19
0.25
0.60

0.60
0.33

1.10
0.31
0.64
0.80
0.63
1.10

0.26
0.37
0.26

0.37
0.37

0.88
0.32
0.81
0.50
0.40

166
136
172
181

176

max4)
277

Sample D

0.67
0.31
0.39
1.10

1.10
0.75

2.13
0.48
0.83
1.34
0.92
2.13

0.40
0.58
0.38

0.58
0.54

1.66
0.49
0.94
0.83
0.55

262
203
277
290

275

max4)
421

17
4
1
3
2
4
3

16
4
3
2
4
3

13
4
1
2
2
4

10
4
1
2
1
2

1
2

3
1
3

10

1st survey

Participants

4
2
6
2

19
5

18
4
4
2
6
2

4
2
6

15
3

11
3
2
2
3
1

6
1
2
2
2
3

16

2nd survey

2
2
4
2

12
2

12
2
2
2
4
2

2
2
4

10
2

7
2
1
2
1
1

1
2

3
1
1

8

both surveys
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total ratio
lathosterol to

LC-MS (deuterium)

GC-MS (deuterium)
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GC-FID (5αcholestane)
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GC-MS (deuterium)

LC-MS (deuterium)

total ratio
cholestanol to
GC-FID (5αcholestane)
GC-MS (5αcholestane)
GC-MS
(epicoprostanol)
GC-MS (5αcholestane)
GC-MS (deuterium)

H

4.33

1.74

8.42

0.45 ± 0.49

4.79

4.65

109.6%

0.16

1.99

0.52 ± 0.57

4.95

5.32

4.31 ± 3.61

90.8%

3.48 ± 0.39

4.12 ± 3.74

3.6%

4.20 ± 2.06

3.45

3.16 ± 0.11

GC-FID (5αcholestane)
GC-FID (5αcholestane)
GC-FID (5αcholestane)
GC-MS (5αcholestane)
GC-MS
(epicoprostanol)
GC-MS
(deuterium)
LC-MS
(deuterium)

53.2%

0.75

3.41

3.94 ± 2.10

cholesterol5)

0.73

2.24 ± 2.38

2.46 ± 2.64

107.3%

1.56

1.09 ± 0.47

1.68

38.9%

1.41 ± 1.17

0.90

1.03 ± 0.40

GC-FID (5αcholestane)
GC-FID (5αcholestane)
GC-FID (5αcholestane)
GC-FID
(epicoprostanol)
GC-MS (5αcholestane)
GC-MS
(epicoprostanol)
GC-MS
(deuterium)

campesterol6)

0.60

2.22 ± 0.05

0.94

1.48 ± 1.32

cholesterol5)

1)

3.68 ± 3.02

mean ± SD

8.22

89.1%

8.24

max

8.24

2.2%

2.05

min

Sample B

2.09

2.23 ± 0.05

GC-FID (5αcholestane)
GC-FID (5αcholestane)
GC-FID (5αcholestane)
GC-MS (5αcholestane)
GC-MS
(epicoprostanol)
LC-MS
(deuterium)

82.4%

CV

4)

2.05

3.68 ± 3.04

cholesterol5)

mean ± SD

3)

109.2%

83.8%

11.2%

49.0%

106.3%

43.2%

82.8%

2.3%

82.1%

CV

2)

0.14

2.16

0.56

2.09

min

3)

1.89

8.48

3.93

8.22

max

4)

0.55 ± 0.28

5.50 ± 0.81

3.12 ± 0.77

2.44

3.68 ± 3.61

2.61

2.42

1.80 ± 0.43

3.71 ± 1.86

51.5%

14.8%

24.6%

97.9%

23.7%

50.1%

9.4%

20.8%

1.28 ± 0.27
1.26 ± 0.12

81.2%

33.1%

31.4%

99.5%

9.0%

67.1%

CV

2)

0.87 ± 0.71

1.46

1.22

1.51 ± 0.50

1.28 ± 0.40

4.83

1.05 ± 1.05

2.78

1.64

1.68 ± 0.15

2.10 ± 1.41

mean ± SD

1)

Sample C

2)

Sample A
1)

Second survey
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3)

0.22

1.13

0.37

0.27

min

Table 3
Results of cholesterol corrected non-cholesterol sterols and ratio lathosterol to campesterol submitted by GC–MS and LC–MS methods.

1.48

6.23

2.07

4.83

max

4)

1)

0.54 ± 0.30

6.15 ± 1.69

2.91 ± 0.60

2.81

3.02 ± 2.83

2.60

2.06

1.79 ± 0.44

3.70 ± 1.98

1.18 ± 0.18
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0.37 ± 0.27

1.48

1.07
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1.05 ± 1.10

1.82

1.46

1.68 ± 0.16

2.41 ± 2.33
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56.4%

27.5%
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93.7%

24.3%
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4.3%

72.9%
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40.5%

104.8%

9.3%

96.5%

CV

2)

0.04
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3)

1.49
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1

1

3

1
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1

2

1
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14.1%

21.4%

0.51 ± 0.07

0.50 ± 0.11

4

37.7%
0.40 ± 0.15

6

2

In the first survey for chromatographically determined cholesterol
ten different laboratories participated. The mean cholesterol concentrations determined by all ten participants were calculated for
sample A (168 ± 42 mg/dL; CV 25.1%) and B (211 ± 45 mg/dL; CV
21.6%). The target concentrations specified by the RfB were 169 mg/dL
(sample A) and 219 mg/dL (sample B). Five out of ten participants did
not determine cholesterol concentrations within a ± 15% range of the
target value. One participant was identified as outlier (Fig. 1A1, a).
In the second survey part sixteen different laboratories attended
from which eight participated in both surveys. The mean cholesterol
concentrations determined by all sixteen participants were calculated
for sample C (147 ± 43 mg/dL; CV 28.9%) and D (220 ± 73 mg/dL;
CV 33.0%). The target concentrations specified by the reference institute were 139 mg/dL (sample C) and 216 mg/dL (sample D). Only six
out of sixteen participants reported cholesterol values that are within
a ± 15% range of our accepted target value. One participant was
identified as outlier (Fig. 1A2, a).
The differences in reported cholesterol results are difficult for an
interpretation. Probably insufficient fatty acid deconjugation of the
cholesterol esters during alkaline hydrolysis might have impaired the
analysis of some participants. It is noteworthy that even with methods
based on isotope dilution GC-MSD and use of an deuterated internal
standard and the same calibration material two laboratories reported a
difference of about 25%. Since our survey shows that two of the three
laboratories using GC-FID reported excellent results, the present data
does not enable the conclusion that deuterium labelled cholesterol used
as internal standard is superior to the use of 5α-cholestane or epicoprostanol. The greatest variations in cholesterol determination were
obtained using methods based on LC-MSD.

22.3%
0.46 ± 0.10

19.5%
0.50 ± 0.10

60.9%
0.41 ± 0.25

59.9%
0.88 ± 0.53

118.3%
0.72 ± 0.85

[μg/μg].
6)

[μg/mg],
maximum value,
2)

5.8%
0.29 ± 0.02

mean value with standard deviation,
1)

43.6%
0.39 ± 0.17

coefficient of variation,

3)

minimum value,

0.96 ± 0.88

0.27 ± 0.01

0.36 ± 0.14

0.29 ± 0.08
32.2%

GC-FID (5αcholestane)
GC-MS (5αcholestane)
GC-MS
(epicoprostanol)
GC-MS (deuterium)

GC-FID (5αcholestane)
GC-MS (5αcholestane)
GC-MS
(epicoprostanol)
GC-MS
(deuterium)

0.29 ± 0.09

min3)
CV2)

In the first survey for chromatographic analysis of serum 5α-cholestanol ten different laboratories participated. The mean 5α-cholestanol concentration determined by all ten participants were calculated
for sample A (0.515 ± 0.438 mg/dL; CV 85.1%) and B
(0.632 ± 0.530 mg/dL; CV 83.9%). Therefore, none of the participants
determined 5α-cholestanol concentrations within a ± 15% range of the
mean value calculated of the reported of all participants. The concentrations submitted by four out of ten laboratories were identified as
outliers (Fig. 1 B1, a to d) and new corrected mean concentrations for
the remaining six laboratories were calculated (sample A:
0.410 ± 0.079 mg/dL, CV 19.2%; sample B: 0.517 ± 0.120 mg/dL,
CV 23.1%). Out of these remaining six laboratories, four determined
5α-cholestanol concentrations within a ± 15% range of the corrected
mean value.
In the second survey eleven different laboratories attended from
which seven laboratories participated in both surveys. The mean 5αcholestanol concentrations determined by eleven participants were
calculated for sample C (0.380 ± 0.260 mg/dL; CV 68.3%) and D
(0.559 ± 0.445 mg/dL; CV 79.6%). One of the participants determined
5α-cholestanol concentrations within a ± 15% range of the mean value
of all participants and four participants reported results which are
identified as outliers (Fig. 1 B2, a to d). The new corrected mean concentration for the remaining seven laboratories was calculated as
(sample C: 0.322 ± 0.111 mg/dL, CV 34.4%; sample D:
0.465 ± 0.183 mg/dL, CV 39.4%). Only one out of the seven remaining laboratories reported results within a ± 15% range of the
corrected mean value.
The first survey revealed a 20-fold variation in the individual results
between the highest and lowest reported concentration. Also, the
second survey revealed widely scattered concentrations with four distinct outliers. Even after the exclusion of these outliers, a 2.5 fold
variation between the highest and lowest included concentrations

4)

92.1%

4.1%

40.2%

28.0%

min3)
CV2)
mean ± SD1)
mean ± SD1)

max4)

Sample B
Sample A

First survey
H

Table 3 (continued)

3.2. 5α-cholestanol

5)

max4)
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max4)
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max4)

2

60.3%
0.88 ± 0.53

2

2

mean ± SD1)
CV2)
mean ± SD1)
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Sample D
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2
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Fig. 1. Distribution of absolute cholesterol and non-cholesterol sterol concentrations analyzed by GC–MS and LC–MS methods in the first descriptive and second
interventional survey. Values a–e in the figures A1-E2 are regarded as outliers.
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Fig. 2. Distribution of calculated cholesterol corrected non-cholesterol concentrations and ratio lathosterol to campesterol in the first descriptive and second interventional survey. Values a–e in the figures A1-D2 are regarded as outliers.

persisted in the second survey. One of the major problems with the 5αcholestanol determination may be related to the fact that 5α-cholestanol has very similar chromatographic properties to cholesterol, whose
concentration in serum are 300 fold higher. Therefore, the separation
performance of the chromatographic system may be a critical for a
reliable 5α-cholestanol quantification.

3.3. Lathosterol
In the first part of the survey for assay of lathosterol thirteen different laboratories participated. The mean lathosterol concentrations
determined by all thirteen participants were calculated for sample A
(0.216 ± 0.197 mg/dL; CV 91.0%) and B (0.257 ± 0.207 mg/dL; CV
80.5%). None of the participants reported lathosterol levels within
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a ± 15% range of the mean value of all participants. The concentrations
submitted by five of the thirteen laboratories were regarded as outliers
(Fig. 1 C1, a and e) and new, corrected mean concentrations for the
remaining eleven laboratories were calculated (sample A:
0.158 ± 0.033 mg/dL, CV 20.6%; sample B: 0.201 ± 0.044 mg/dL,
CV 21.7%). After the correction for the outlier values five of the remaining eleven laboratories reported lathosterol concentrations within
a ± 15% range of the corrected mean value.
In the second survey fifteen different laboratories attended from
which ten laboratories participated in both surveys. The mean lathosterol concentration obtained from all fifteen participants were calculated for sample C (0.197 ± 0.086 mg/dL; CV 43.5%) and D
(0.281 ± 0.145 mg/dL; CV 51.8%). Four of the participants determined lathosterol concentrations within a ± 15% range of the mean
value of all participants. In the second survey, four participants were
identified as outliers (Fig. 1 C2, a to d) and new corrected mean concentrations for the remaining eleven laboratories were calculated
(sample C: 0.183 ± 0.047 mg/dL, CV 25.5%; sample D:
0.265 ± 0.076 mg/dL, CV 28.5%). Only five of the remaining laboratories reported results within a ± 15% range of the common mean
value.
In both surveys very high variations of lathosterol concentrations
were reported. After exclusion of 4 outliers in the second survey a 2.0
fold variation between the reported results remained.
While chromatographic separation of 5α-cholestanol in presence of
high serum cholesterol concentrations is very challanging, lathosterol
can be chromatographically well separated from other non-cholesterol
sterols. However, incorrect peak identification and/or incorrect integration of the peak could lead to these discrepancies in the results
reported from the different laboratories.

3.5. Sitosterol
In the first survey part for chromatographically determined sitosterol seventeen different laboratories participated. The mean sitosterol
concentrations determined by all seventeen participants were calculated for sample A (0.334 ± 0.335 mg/dL; CV 100.2%) and B
(0.401 ± 0.353 mg/dL; CV 88.0%). Two of the participants determined sitosterol concentrations within a ± 15% range of the mean
value of all participants. The concentrations submitted by six of the
seventeen laboratories were identified as outliers (Fig. 1 E1, a to f) and
new corrected mean concentrations for the remaining eleven laboratories were calculated (sample A: 0.276 ± 0.055 mg/dL, CV 20.1%;
sample B: 0.345 ± 0.071 mg/dL, CV 20.5%). Of the remaining eleven
laboratories four determined sitosterol concentrations within a ± 15%
range of the corrected mean value.
In the second survey, nineteen different laboratories participated
from which twelve laboratories participated in both surveys. The mean
sitosterol concentrations determined by all eighteen participants were
calculated for sample C (0.248 ± 0.116 mg/dL; CV 46.8%) and D
(0.387 ± 0.237 mg/dL; CV 61.3%). Only three of the nineteen participants reported sitosterol concentrations within a ± 15% range of the
mean value of all participants. In the second survey four participants
were identified as outliers (Fig. 1 E2, a to d) and a corrected mean
concentrations for the remaining sixteen laboratories were calculated
(sample C: 0.206 ± 0.055 mg/dL, CV 26.6%; sample D:
0.317 ± 0.095 mg/dL, CV 30.1%). Only six of the remaining laboratories determined results within a ± 15% range of the corrected mean
value.
Also, in both surveys a high variation in the reported sitosterol
concentrations was observed. After removing 4 outliers in the second
survey there was still a 2.0 fold difference between the highest and the
lowest reported value.

3.4. Campesterol
In the first survey for chromatographically determined campesterol
sixteen different laboratories participated. The mean campesterol concentrations determined by all sixteen participants were calculated for
sample
A
(0.597 ± 0.321 mg/dL;
CV
53.8%)
and
B
(0.760 ± 0.410 mg/dL; CV 54.0%). Five of the participants reported
campesterol concentrations within a ± 15% range of the mean value of
all participants. The concentrations reported by seven of the sixteen
laboratories were identified as outliers (Fig. 1 D1, a to g) and new
corrected mean concentrations for the remaining eleven laboratories
were calculated (sample A: 0.488 ± 0.106 mg/dL, CV 21.8%; sample
B: 0.656 ± 0.134 mg/dL, CV 20.4%). Four of these remaining nine
laboratories determined campesterol concentrations within a ± 15%
range of the corrected mean value.
In the second survey, eighteen different laboratories participated
from which twelve laboratories participated in both surveys. The mean
campesterol concentrations determined by all eighteen participants
were calculated as for sample C (0.437 ± 0.247 mg/dL; CV 56.5%) and
D (0.677 ± 0.458 mg/dL; CV 67.7%). Two of the eighteen participants
determined campesterol concentrations within a ± 15% range of the
mean value of all participants. In the second survey five participants
were regarded as outliers (Fig. 1 D2, a to e) and corrected mean concentrations for the remaining thirteen laboratories were calculated
(sample C: 0.373 ± 0.135 mg/dL, CV 36.1%; sample D:
0.549 ± 0.187 mg/dL, CV 33.9%). Only three of the remaining laboratories determined results within an ± 15% range of the corrected
mean value.
For the measurement of campesterol very high variations were reported in both surveys. After exclusion of 5 outliers in the second survey
there was still a 2.5 fold difference between the highest and lowest
reported value.

3.6. Ratios of 5α-cholestanol, lathosterol, and campesterol to cholesterol
and lathosterol to campesterol
Since the ratios of 5α-cholestanol, lathosterol, and campesterol to
cholesterol and lathosterol to campesterol are the most common surrogate markers for absorption and synthesis rates, we calculated these
ratios for sample A to D for all participants. The results and subgroup
analysis from the both surveys are listed in details in Table 2 and shown
in Fig. 2 A1 to D2.
3.6.1. 5α-cholestanol to cholesterol
In the first survey part four participants were included with calculated results for sample A (3.68 ± 3.04 μg/mg; CV 82.4%) and B
(3.68 ± 3.02 μg/mg; CV 82.1%). None of the participants determined
5α-cholestanol to cholesterol ratio within a ± 15% range of the mean
value of all participants and one participant was identified as outlier
(Fig. 2 A1, a). The new corrected mean value for the remaining three
laboratories were calculated for A (2.17 ± 0.11 μg/mg; CV 4.9%) and
B (2.17 ± 0.08 μg/mg; CV 3.8%). All the remaining laboratories determined the 5α-cholestanol to cholesterol ratio within a ± 15% range
of the corrected mean value.
In the second survey part seven participants were included with
calculated results for sample A (2.10 ± 1.41 μg/mg; CV 67.1%) and B
(2.41 ± 2.33 μg/mg; CV 96.5%). None of the participants determined
5α-cholestanol to cholesterol ratio within a ± 15% range of the mean
value of all participants and two participants were identified as outliers
(Fig. 2 A2, a and b). The new corrected mean value for the remaining
five laboratories were calculated for A (1.92 ± 0.49 μg/mg; CV 25.6%)
and B (1.69 ± 0.17 μg/mg; CV 10.1%). Three of the remaining five
laboratories determined the 5α-cholestanol to cholesterol ratio within
a ± 15% range of the corrected mean value.
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3.6.2. Lathosterol to cholesterol
In the first survey part seven participants were included with calculated results for sample A (1.48 ± 1.32 μg/mg; CV 89.1%) and B
(1.41 ± 1.17 μg/mg; CV 82.8%). Two of the participants determined
lathosterol to cholesterol ratio within a ± 15% range of the mean value
of all participants and three participants were identified as outliers
(Fig. 2 B1, a to c). The new corrected mean value for the remaining four
laboratories were calculated for A (1.17 ± 0.41 μg/mg; CV 35.4%) and
B (1.16 ± 0.39 μg/mg; CV 33.7%). None of the laboratories determined the lathosterol to cholesterol ratio within a ± 15% range of
the corrected mean value.
In the second survey part eleven participants were included with
calculated results for sample A (1.28 ± 0.40 μg/mg; CV 31.4%) and B
(1.15 ± 0.47 μg/mg; CV 40.5%). Five of the participants determined
lathosterol to cholesterol ratio within a ± 15% range of the mean value
of all participants and three participants were identified as outliers
(Fig. 2 B2, a to c). The new corrected mean value for the remaining five
laboratories were calculated for A (1.28 ± 0.15 μg/mg; CV 11.7%) and
B (1.25 ± 0.15 μg/mg; CV 12.2%). Six of the remaining eight laboratories determined the lathosterol to cholesterol ratio within a ± 15%
range of the corrected mean value.

cholestanol, lathosterol- and campesterol to cholesterol were calculated
to be between 31.4% and 96.5%, respectively. The coefficient of variation for the average value for the ratio of lathosterol to campesterol
were calculated between 51.5% to 109.2%. Here is to notice that the
ratio of lathosterol to campesterol shows even higher variations probably because of the analytical challenges. It is noteworthy that this
survey revealed a high variation for ratios of NCS to cholesterol which
prevents definition of resilient threshold values.
4. Common discussion
Unlikely to the other NCS assays, a target value for cholesterol could
be reported in the present survey. For NCS assays the reported values
could only be compared to the mean of values obtained from all participants or to a corrected mean value after removal of defined outlier.
Thus, the true NCS analyte concentration could not be referred with
certainty in any of these assays. Absolute reference methods have been
developed for some analytes of diagnostic importance but for most
analytes there is no “golden method” and we are thus restricted to
compare results between different laboratories [9,10].
However, with the collected survey data on hand it is not possible to
sufficiently evaluate the best chromatographic method for cholesterol
and NCS determination in plasma or serum. It can be generally considered that the quality of the present type of cholesterol and NCS
analysis is directly dependent upon the skill and experience of the
analyst, the limitations of the analysis method, the sample quality and
sampling itself, as well as on the quality of the calibration material and
used internal standards. Within the survey six different methods were
used whereby all measurements dependent upon a critical chromatographic step, either gas- or liquid chromatography. Due to higher
chromatographic efficiency and the reduced influence of matrix effects
on ionisation and signal suppression, one would expect less analytical
problems with gas chromatography compared to liquid chromatography. As ideal standard for cholesterol and NCS analysis it can be
expected that the use of the same deuterium or 13C isotope labelled
molecule will result in the most precise mass spectrometric analysis. In
respect to that it is to mention that the internationally accepted reference method for cholesterol is based on isotope-dilution mass-spectrometry combined with GC [8,9,11–13].
The use of common quantified calibration material slightly improved the variation of reported results even since individual laboratories and the number of participants is different in the two survey
parts. Here, three points should be emphasized: First of all, commercially available standards do not always have the required purity of
99.0% needed. Quality and purity of standard materials used should
always be controlled if possible. In addition to this, the weighing of
small milligram amounts is often challenging and is prone to generate
errors. To avoid these effects of impurities and weighing, we recommend to quantify the cholesterol and NCS calibration solutions by
GC-FID (5α-cholestanol) before use. Lastly, calibration solutions independent if self-prepared or commercially sourced have a limited
bench stability. Using the same solution over years might alter internal
analyte concentrations. Therefore, used stock solutions should be newly
prepared or re-quantified after a certain usage time by the above described method and old stock solutions should be analysed alongside
the new for a short overlapping period.

3.6.3. Campesterol to cholesterol
In the first survey part eight participants were included with calculated results for sample A (3.94 ± 2.10 μg/mg; CV 53.2%) and B
(4.20 ± 2.06 μg/mg; CV 49.0%). None of the participants determined
campesterol to cholesterol ratio within a ± 15% range of the mean
value of all participants and two participants were identified as outliers
(Fig. 2 C1, a and b). The new corrected mean value for the remaining
six laboratories were calculated for A (3.56 ± 0.99 μg/mg; CV 27.9%)
and B (3.81 ± 1.17 μg/mg; CV 30.6%). Two laboratories determined
the campesterol to cholesterol ratio within a ± 15% range of the corrected mean value.
In the second survey part thirteen participants were included with
calculated results for sample A (3.71 ± 1.86 μg/mg; CV 50.1%) and B
(3.70 ± 1.98 μg/mg; CV 53.5%). One of the participants determined
campesterol to cholesterol ratio within a ± 15% range of the mean
value of all participants and five participants were identified as outliers
(Fig. 2 C2, a and e). The new corrected mean value for the remaining
eight laboratories were calculated for A (3.24 ± 1.06 μg/mg; CV
32.7%) and B (3.24 ± 1.01 μg/mg; CV 31.3%). One of the remaining
eight laboratories determined the campesterol to cholesterol ratio
within a ± 15% range of the corrected mean value.
3.6.4. Lathosterol to campesterol
In the first survey part twelve participants were included with calculated results for sample A (0.45 ± 0.49 μg/μg; CV 109.6%) and B
(0.52 ± 0.57 μg/μg; CV 109.2%). One of the participants determined
lathosterol to campesterol ratio within a ± 15% range of the mean
value of all participants and six participants were identified as outliers
(Fig. 2 D1, a to f). The new corrected mean value for the remaining six
laboratories were calculated for A (0.35 ± 0.09 μg/μg; CV 26.2%) and
B (0.33 ± 0.08 μg/μg; CV 24.1%). One laboratory determined the lathosterol to campesterol ratio within a ± 15% range of the corrected
mean value.
In the second survey part fifteen participants were included with
calculated results for sample A (0.55 ± 0.28 μg/μg; CV 51.5%) and B
(0.54 ± 0.30 μg/μg; CV 56.4%). Seven of the participants determined
lathosterol to campesterol ratio within a ± 15% range of the mean
value of all participants and two participants were identified as outliers
(Fig. 2 D1, a and b). The new corrected mean value for the remaining
eight laboratories were calculated for A (0.50 ± 0.10 μg/μg; CV
20.1%) and B (0.50 ± 0.09 μg/μg; CV 18.7%). Seven of the remaining
eleven laboratories determined the lathosterol to campesterol ratio
within a ± 15% range of the corrected mean value.
The coefficient of variation for the average value for the ratio of 5α-

5. Conclusions
We found surprisingly high variations in cholesterol and NCS concentrations obtained from analytical assays based on chromatographic
separation. The participating laboratories specialized in lipid analysis
reported astoundingly strong differences in the concentrations of neutral sterols in both survey parts. However, the use of common calibration materials slightly improved the variations in the reported concentrations, whereby still high variations were obtained in the second
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interventional survey part. In glance to this situation the evaluation of
normal plasma or serum reference concentrations of neutral sterols is
very challenging and nearly impossible. Furthermore, this survey gives
evidence for the urgent need for quality control programs with interchange of samples between different laboratories in order to harmonize
the chromatographic analysis of cholesterol and NCS from serum or
plasma samples. In the future we intent to provide following ring trials
for the quantification of cholesterol, oxidized cholesterols and neutral
sterols based on chromatographic separation techniques and mass
spectrometric or flame ionization detection methods.

References
[1] I. Björkhem, T. Miettinen, E. Reihner, S. Ewerth, B. Angelin, K. Einarsson,
Correlation between serum levels of some cholesterol precursors and activity of
HMG-CoA reductase in human liver, J. Lipid Res. 28 (10) (1987) 1137–1143.
[2] T.A. Miettinen, R.S. Tilvis, Y.A. Kesaniemi, Serum cholestanol and plant sterol levels in relation to cholesterol metabolism in middle-aged men, Metabolism 38 (2)
(1989) 136–140.
[3] R.S. Tilvis, T.A. Miettinen, Serum plant sterols and their relation to cholesterol
absorption, Am. J. Clin. Nutr. 43 (1) (1986) 92–97.
[4] T.A. Miettinen, R.S. Tilvis, Y.A. Kesaniemi, Serum plant sterols and cholesterol
precursors reflect cholesterol absorption and synthesis in volunteers of a randomly
selected male population, Am. J. Epidemiol. 131 (1) (1990) 20–31.
[5] D. Mackay, P.J. Jones, Evaluation of methods for the determination of cholesterol
absorption and synthesis in humans, Atherosclerosis 218 (2) (2011) 253–262.
[6] D.S. Mackay, P.J. Jones, Plasma noncholesterol sterols: current uses, potential and
need for standardization, Curr. Opin. Lipidol. 23 (3) (2012) 241–247.
[7] D.S. Mackay, P.J. Jones, S.B. Myrie, J. Plat, D. Lütjohann, Methodological considerations for the harmonization of non-cholesterol sterol bio-analysis, J.
Chromatogr. B Anal. Technol. Biomed. Life Sci. 957 (2014) 116–122.
[8] Bundesärztekammer, Richtlinie der Bundesärztekammer zur Qualitätssicherung
laboratoriumsmedizinischer Untersuchungen, Deutsches Ärzteblatt 38 (2014)
A1583–A1618.
[9] H. Gylling, P. Simonen, L. Kaipiainen, I. Wester, Methodological aspects of phytosterol measurements in biological samples, Curr. Med. Chem. (2018).
[10] C.T. Srigley, S.L. Hansen, S.A. Smith, A. Abraham, E. Railey, X. Chen, S.H. Chooi,
L.M. Clement, M. Dao, A.R.F. Kia, B. Mitchell, M. Mogla, J.A.R. Ortiz, K. Persons,
E. von Kries, G. Ware, J. Wubben, R. Cantrill, Sterols and stanols in foods and
dietary supplements containing added phytosterols: a collaborative study, J. Am.
Oil Chem. Soc. 85 (2018) 247–257.
[11] S.H. Edwards, M.M. Kimberly, S.D. Pyatt, S.L. Stribling, K.D. Dobbin, G.L. Myers,
Proposed serum cholesterol reference measurement procedure by gas chromatography-isotope dilution mass spectrometry, Clin. Chem. 57 (4) (2011) 614–622.
[12] I. Björkhem, R. Blomstrand, S. Eriksson, O. Falk, A. Kallner, L. Svensson, G. Ohman,
Use of isotope dilution–mass spectrometry for accuracy control of different routine
methods used in clinical chemistry, Scand. J. Clin. Lab. Invest. 40 (6) (1980)
529–534.
[13] I. Björkhem, R. Blomstrand, L. Svensson, Serum cholesterol determination by mass
fragmentography, Clin. Chim. Acta 54 (2) (1974) 185–193.

Fundings
We gratefully acknowledge funding for materials, statistics, and
travel expenses to the Foundation for Pathobiochemistry and Molecular
Diagnostics, German Society of Clinical Chemistry and Laboratory
Medicine, Germany. The work in University of Valencia was financed
by CICYT-FEDER (AGL2008−02591-C02-01) and MINECO-FEDER
(AGL2012−39503-C02-01). The work at Universitario Miguel Servet,
Zaragoza, Spain was funded by Fondo de Investigación Sanitaria (FIS;
PI15/01983). Work in Swansea was supported by the UK Biotechnology
and Biological Sciences Research Council (BBSRC, grant numbers BB/
I001735/1 and BB/L001942/1).
Acknowledgements
The basic initiatives for the performance of these surveys were
started during and the results presented at the annual meetings of the
European Network for Oxysterol Research (ENOR; https://www.
oxysterols.net/). Most of the survey participants are members of the
ENOR group.

125

